This cluster is routine and non-informative. The $2.09M in sales is immaterial relative to Nuvalent's $9.8B market cap, and both executives exercised options simultaneously, consistent with pre-planned diversification. No bearish signal. Monitor next clinical data readout or regulatory catalyst for the underlying pipeline.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Jul 6 $123.72entry
- T+1 · 4mo ago +0.04%α +0.52% · $123.77
- T+5 · 4mo ago +0.15%α −0.34% · $123.90
- T+20 · due 4mo ago Pending
- T+60 · due 7w ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two C-suite executives at Nuvalent (CFO and CDO) sold a combined $2.09M in open-market shares this week, all on the same day after exercising stock options. While the cluster involves top officers, the $2.09M represents only ~0.02% of the $9.8B market cap, a trivial, routine proportion consistent with planned option exercises and tax diversification. The insider cluster does not signal material non-public information.
Key Financial Metrics
Key Facts
- CFO Alexandra Balcom sold 11,430 shares at $123.58 for $1.41M on July 1, 2026.
- CDO Darlene Noci sold 5,500 shares at $123.51 for $679K on June 29, 2026, and an additional 23,000 shares at $123.59 for $2.84M on July 1, 2026.
- All sales followed same-day exercise of stock options at de minimis exercise prices ($0–$18.93), indicating routine cashless exercises and share sales for tax purposes.
- Total open-market sales by the cluster: ~$2.09M (aggregate unique sales after isolating derivative exercises). This equals ~0.02% of Nuvalent's $9.8B market cap.
- Both executives exercised options concurrently with their sales, consistent with pre-arranged or vesting-driven plans.
Financial Impact
Total insider open-market sales of ~$2.09M, representing 0.02% of market cap, trivial absolute and relative size.
Risk Factors
- Continued insider selling at a higher clip in coming weeks could signal a change in sentiment, watch for additional Form 4 filings.
- Nuvalent is a pre-commercialization biotech; fundamental risk remains tied to pipeline execution, not insider trading patterns.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NUVL-1783409687997 |
Track record
18 reports on NUVL
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +21.01% at T+60 after the Apr 7, 2026 report. 4 of 8 went positive at some point.
Filters
- Jul 27, 202616w ago 15-12G Neutral 3/10 No price data
- Jul 15, 202617w ago 25-NSE Neutral 3/10 Entry $123.96 No price data
- Jul 15, 202617w ago 8-K Bullish 5/10 Entry $123.96 No price data
- Jul 8, 202618w ago Insider Cluster Neutral 3/10 Entry $123.80 No price data
- Jul 6, 202619w ago Insider Cluster Neutral 3/10 Viewing Entry $123.72 No price data
- Jun 11, 202622w ago Insider Cluster Neutral 2/10 Entry $123.25 to $123.90 ▲ +0.53% −1.25% vs SPY
- Jun 10, 202622w ago Insider Cluster Neutral 3/10 Entry $123.45 to $123.83 ▲ +0.31% −1.58% vs SPY
- Jun 9, 202622w ago 8-K Bullish 8/10 Entry $123.25 to $123.77 ▲ +0.42% −1.02% vs SPY
- May 7, 202627w ago 8-K Neutral 4/10 Entry $102.40 to $90.18 ▼ −11.93% −15.07% vs SPY
- Apr 29, 202628w ago Insider Cluster Neutral 2/10 Entry $99.10 to $107.38 ▲ +8.36% +2.90% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers